Cohance Lifesciences invests USD 18 million to advance ADC strategy

Strategic Transactions View source PDF Explain this filing

COHANCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.6%Reaction day

₹459.00

prior close

₹463.30

announcement price

After-mkt

timing

Nifty Smallcap 250market+0.2%-0.8% vs market

Pharmaceuticals peers, median of 174sector-0.0%-0.6% vs sector

On the reaction day the stock moved 0.8 pts less than Nifty Smallcap 250 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

+1.0

15m

+0.6

30m

+0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.6+0.2-0.8-0.0-0.6

Next day

-1.6+0.2-1.8+0.1-1.7

-1.0+0.4-1.5+0.8-1.8

-3.6-0.1-3.5+0.1-3.7

-3.3-0.1-3.2+0.8-4.0

-4.2-0.6-3.7-0.0-4.2

-5.8-3.2-2.7-1.5-4.3

15d

-1.0-3.2+2.1-0.9-0.2

-2.8-4.3+1.5-2.9+0.1

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Cohance Lifesciences announced two transactions totalling USD 18 million to strengthen its Antibody Drug Conjugate (ADC) strategy. It will invest USD 13 million to raise its stake in NJ Bio from 56 percent to 67.3 percent by buying out minority holders. It will also invest USD 5 million for a 65 percent controlling stake in Aruka Bio, making it a direct subsidiary. Both deals are funded through internal accruals and are expected to close by end of September 2026, subject to approvals.

Likely market impact

Strengthens Cohance's ADC pipeline and CRDMO capabilities; expands US biotech footprint through two subsidiaries.